Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$59.70 USD
+0.64 (1.08%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $59.70 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
EXAS 59.70 +0.64(1.08%)
Will EXAS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EXAS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EXAS
What Role Will Macro Data Play, Before the U.S. Election?
Does Exact Sciences (EXAS) Have the Potential to Rally 34.13% as Wall Street Analysts Expect?
EXAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches
Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study
Why You Should Add Exact Sciences (EXAS) to Your Portfolio
Other News for EXAS
Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study
Exact Sciences: Cost Optimization And Product Strength
Baron Discovery Fund Q2 2024 Shareholder Letter
New Modeling Data Show the Cologuard? Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion
Glenview Capital's Q2 moves include selling Broadcom after just one quarter, exiting Meta